Last reviewed · How we verify

NCT03966573

Femoral Lengthening Might Impair Physical Function and Lead to Structural Changes in Adjacent Joints

Completed NA Last updated 26 February 2021
What this trial tests

NA trial testing Radiographic imaging in Leg Length Inequality in 10 participants. Completed in 11 October 2019.

Timeline
6 March 2019
Primary endpoint
11 October 2019
11 October 2019

Quick facts

Lead sponsorOslo University Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposescreening
Enrollment10
Start date6 March 2019
Primary completion11 October 2019
Estimated completion11 October 2019
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Oslo University Hospital

Who can join

Eligibility, any sex, with Leg Length Inequality or Leg; Lengthening. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates function, quality of life and development of hip- and knee osteoarthritis minimum 15 years after unilateral femoral lengthening on people with idiopathic or post-traumatic anisomelia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Femoral lengthening might impair physical function and lead to structural changes in adjacent joints: 10 patients with 27 to 34 years' follow-up.
    Bjørge PA, Tveter AT, Steen H, Gunderson R, et al · · 2021 · PMID 33410356 · DOI 10.1080/17453674.2020.1866864

Verify or expand the search:

Other trials of Radiographic imaging

Trials testing the same drug.

Other recruiting trials for Leg Length Inequality

Currently open trials in the same condition.

Other Oslo University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03966573.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing